Effect of single-dose rituximab on primary glomerular diseases

Hidekazu Sugiura, Takashi Takei, Mitsuyo Itabashi, Misao Tsukada, Takahito Moriyama, Chiari Kojima, Toshiharu Shiohira, Ari Shimizu, Yuki Tsuruta, Nobuyuki Amemiya, Tetsuya Ogawa, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: A paradigm shift from such toxic 'nonspecific' therapies to selective immunomodulating regimens is necessary for glomerular diseases. Rituximab, which acts by inhibiting CD20-mediated B cell proliferation and differentiation, could be effective in the treatment of nephrotic syndrome as shown in recent reports. Design: To assess the effects of rituximab in patients with primary glomerular diseases, including minimal-change disease, immunoglobulin A (IgA) nephropathy, focal segmental glomerulonephritis, membranous nephropathy and membranoproliferative glomerulonephritis, we performed a prospective trial of the effects of single-dose rituximab therapy in 24 patients. We prospectively evaluated the serum and urinary biochemical parameters before and after 6 months of therapy. Results: In all of the patients studied, depletion of CD19 and CD20 cells was noted, with significant reduction in the degree of proteinuria from 3.7 ± 3.4 g/day at baseline to 1.3 ± 2.0 g/day at 6 months after the drug administration (p = 0.002). However, no significant changes of the serum creatinine, urinary RBC sediment, serum CD4/8 or serum IL-4 levels were observed at 6 months after the drug administration. In subjects with IgA nephropathy, while depletion of CD19 and CD20 cells was noted, no significant change in the severity of proteinuria was observed at 6 months after the drug administration as compared with the level at the baseline. Conclusion: For the treatment of primary glomerular diseases, the use of a single dose of rituximab is demonstrated with no serious adverse events. Further study of the mechanism of action of rituximab in successfully treated patients could encourage new perspectives in the treatment of primary glomerular diseases.

Original languageEnglish (US)
JournalNephron - Clinical Practice
Volume117
Issue number2
DOIs
StatePublished - Jan 2011

Fingerprint

IGA Glomerulonephritis
Membranous Glomerulonephritis
Serum
Proteinuria
Therapeutics
Pharmaceutical Preparations
Membranoproliferative Glomerulonephritis
Lipoid Nephrosis
Poisons
Nephrotic Syndrome
Glomerulonephritis
Interleukin-4
Rituximab
Cell Differentiation
Creatinine
B-Lymphocytes
Cell Proliferation

Keywords

  • Primary glomerular disease
  • Rituximab

ASJC Scopus subject areas

  • Nephrology

Cite this

Sugiura, H., Takei, T., Itabashi, M., Tsukada, M., Moriyama, T., Kojima, C., ... Nitta, K. (2011). Effect of single-dose rituximab on primary glomerular diseases. Nephron - Clinical Practice, 117(2). https://doi.org/10.1159/000319656

Effect of single-dose rituximab on primary glomerular diseases. / Sugiura, Hidekazu; Takei, Takashi; Itabashi, Mitsuyo; Tsukada, Misao; Moriyama, Takahito; Kojima, Chiari; Shiohira, Toshiharu; Shimizu, Ari; Tsuruta, Yuki; Amemiya, Nobuyuki; Ogawa, Tetsuya; Uchida, Keiko; Tsuchiya, Ken; Nitta, Kosaku.

In: Nephron - Clinical Practice, Vol. 117, No. 2, 01.2011.

Research output: Contribution to journalArticle

Sugiura, H, Takei, T, Itabashi, M, Tsukada, M, Moriyama, T, Kojima, C, Shiohira, T, Shimizu, A, Tsuruta, Y, Amemiya, N, Ogawa, T, Uchida, K, Tsuchiya, K & Nitta, K 2011, 'Effect of single-dose rituximab on primary glomerular diseases', Nephron - Clinical Practice, vol. 117, no. 2. https://doi.org/10.1159/000319656
Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron - Clinical Practice. 2011 Jan;117(2). https://doi.org/10.1159/000319656
Sugiura, Hidekazu ; Takei, Takashi ; Itabashi, Mitsuyo ; Tsukada, Misao ; Moriyama, Takahito ; Kojima, Chiari ; Shiohira, Toshiharu ; Shimizu, Ari ; Tsuruta, Yuki ; Amemiya, Nobuyuki ; Ogawa, Tetsuya ; Uchida, Keiko ; Tsuchiya, Ken ; Nitta, Kosaku. / Effect of single-dose rituximab on primary glomerular diseases. In: Nephron - Clinical Practice. 2011 ; Vol. 117, No. 2.
@article{d80db8dec24740ddb75f2d5cb54eefd6,
title = "Effect of single-dose rituximab on primary glomerular diseases",
abstract = "Background: A paradigm shift from such toxic 'nonspecific' therapies to selective immunomodulating regimens is necessary for glomerular diseases. Rituximab, which acts by inhibiting CD20-mediated B cell proliferation and differentiation, could be effective in the treatment of nephrotic syndrome as shown in recent reports. Design: To assess the effects of rituximab in patients with primary glomerular diseases, including minimal-change disease, immunoglobulin A (IgA) nephropathy, focal segmental glomerulonephritis, membranous nephropathy and membranoproliferative glomerulonephritis, we performed a prospective trial of the effects of single-dose rituximab therapy in 24 patients. We prospectively evaluated the serum and urinary biochemical parameters before and after 6 months of therapy. Results: In all of the patients studied, depletion of CD19 and CD20 cells was noted, with significant reduction in the degree of proteinuria from 3.7 ± 3.4 g/day at baseline to 1.3 ± 2.0 g/day at 6 months after the drug administration (p = 0.002). However, no significant changes of the serum creatinine, urinary RBC sediment, serum CD4/8 or serum IL-4 levels were observed at 6 months after the drug administration. In subjects with IgA nephropathy, while depletion of CD19 and CD20 cells was noted, no significant change in the severity of proteinuria was observed at 6 months after the drug administration as compared with the level at the baseline. Conclusion: For the treatment of primary glomerular diseases, the use of a single dose of rituximab is demonstrated with no serious adverse events. Further study of the mechanism of action of rituximab in successfully treated patients could encourage new perspectives in the treatment of primary glomerular diseases.",
keywords = "Primary glomerular disease, Rituximab",
author = "Hidekazu Sugiura and Takashi Takei and Mitsuyo Itabashi and Misao Tsukada and Takahito Moriyama and Chiari Kojima and Toshiharu Shiohira and Ari Shimizu and Yuki Tsuruta and Nobuyuki Amemiya and Tetsuya Ogawa and Keiko Uchida and Ken Tsuchiya and Kosaku Nitta",
year = "2011",
month = "1",
doi = "10.1159/000319656",
language = "English (US)",
volume = "117",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Effect of single-dose rituximab on primary glomerular diseases

AU - Sugiura, Hidekazu

AU - Takei, Takashi

AU - Itabashi, Mitsuyo

AU - Tsukada, Misao

AU - Moriyama, Takahito

AU - Kojima, Chiari

AU - Shiohira, Toshiharu

AU - Shimizu, Ari

AU - Tsuruta, Yuki

AU - Amemiya, Nobuyuki

AU - Ogawa, Tetsuya

AU - Uchida, Keiko

AU - Tsuchiya, Ken

AU - Nitta, Kosaku

PY - 2011/1

Y1 - 2011/1

N2 - Background: A paradigm shift from such toxic 'nonspecific' therapies to selective immunomodulating regimens is necessary for glomerular diseases. Rituximab, which acts by inhibiting CD20-mediated B cell proliferation and differentiation, could be effective in the treatment of nephrotic syndrome as shown in recent reports. Design: To assess the effects of rituximab in patients with primary glomerular diseases, including minimal-change disease, immunoglobulin A (IgA) nephropathy, focal segmental glomerulonephritis, membranous nephropathy and membranoproliferative glomerulonephritis, we performed a prospective trial of the effects of single-dose rituximab therapy in 24 patients. We prospectively evaluated the serum and urinary biochemical parameters before and after 6 months of therapy. Results: In all of the patients studied, depletion of CD19 and CD20 cells was noted, with significant reduction in the degree of proteinuria from 3.7 ± 3.4 g/day at baseline to 1.3 ± 2.0 g/day at 6 months after the drug administration (p = 0.002). However, no significant changes of the serum creatinine, urinary RBC sediment, serum CD4/8 or serum IL-4 levels were observed at 6 months after the drug administration. In subjects with IgA nephropathy, while depletion of CD19 and CD20 cells was noted, no significant change in the severity of proteinuria was observed at 6 months after the drug administration as compared with the level at the baseline. Conclusion: For the treatment of primary glomerular diseases, the use of a single dose of rituximab is demonstrated with no serious adverse events. Further study of the mechanism of action of rituximab in successfully treated patients could encourage new perspectives in the treatment of primary glomerular diseases.

AB - Background: A paradigm shift from such toxic 'nonspecific' therapies to selective immunomodulating regimens is necessary for glomerular diseases. Rituximab, which acts by inhibiting CD20-mediated B cell proliferation and differentiation, could be effective in the treatment of nephrotic syndrome as shown in recent reports. Design: To assess the effects of rituximab in patients with primary glomerular diseases, including minimal-change disease, immunoglobulin A (IgA) nephropathy, focal segmental glomerulonephritis, membranous nephropathy and membranoproliferative glomerulonephritis, we performed a prospective trial of the effects of single-dose rituximab therapy in 24 patients. We prospectively evaluated the serum and urinary biochemical parameters before and after 6 months of therapy. Results: In all of the patients studied, depletion of CD19 and CD20 cells was noted, with significant reduction in the degree of proteinuria from 3.7 ± 3.4 g/day at baseline to 1.3 ± 2.0 g/day at 6 months after the drug administration (p = 0.002). However, no significant changes of the serum creatinine, urinary RBC sediment, serum CD4/8 or serum IL-4 levels were observed at 6 months after the drug administration. In subjects with IgA nephropathy, while depletion of CD19 and CD20 cells was noted, no significant change in the severity of proteinuria was observed at 6 months after the drug administration as compared with the level at the baseline. Conclusion: For the treatment of primary glomerular diseases, the use of a single dose of rituximab is demonstrated with no serious adverse events. Further study of the mechanism of action of rituximab in successfully treated patients could encourage new perspectives in the treatment of primary glomerular diseases.

KW - Primary glomerular disease

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=77955193837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955193837&partnerID=8YFLogxK

U2 - 10.1159/000319656

DO - 10.1159/000319656

M3 - Article

C2 - 20693810

AN - SCOPUS:77955193837

VL - 117

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 2

ER -